Monday, 26 May 2014 08:43

Anticoagulation news items. Week commencing 19th May 2014

Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from EUROMAX trial

European Heart Journal
Analysis (n=2198) found death and major bleeding occurred in 5.1% on bivalirudin, 7.6% on heparin plus routine GPI (HR 0.67; 95% CI 0.46–0.97, p=0.034), and 9.8% on heparins plus bailout GPI (0.52; 0.35–0.75, p=0.006). Rates of stent thrombosis were higher with bivalirudin.


Posterior circulation ischaemic stroke

British Medical Journal
This review aims to demonstrate the importance and challenges of recognising and treating posterior circulation stroke, which accounts for 20-25% of ischaemic strokes. It discusses causes, clinical symptoms and signs, and its diagnosis and management.


Management of Anticoagulation Around Pacemaker and Defibrillator Surgery

This Clinician Update discusses the management of warfarin and the new oral anticoagulants (NOACs) around the time of surgery in patients having defibrillator and pacemaker surgery, illustrated with two case examples, for which recommendations on suggested management are given.


European Medicines Agency recommends approval of simoctogog alfa (Nuwiq®) for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)

European Medicines Agency
The European CHMP has recommended approval of simoctogog alfa (Nuwiq) for the treatment and prophylaxis of bleeding in paediatric and adult patients with haemophilia A (congenital factor VIII deficiency).



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: